HUE038650T2 - Nukleáris képalkotáshoz és sugárterápiához használt kelátorok (kelátképzõk) hatékony szintézise: összetételek és alkalmazások - Google Patents

Nukleáris képalkotáshoz és sugárterápiához használt kelátorok (kelátképzõk) hatékony szintézise: összetételek és alkalmazások

Info

Publication number
HUE038650T2
HUE038650T2 HUE07799253A HUE07799253A HUE038650T2 HU E038650 T2 HUE038650 T2 HU E038650T2 HU E07799253 A HUE07799253 A HU E07799253A HU E07799253 A HUE07799253 A HU E07799253A HU E038650 T2 HUE038650 T2 HU E038650T2
Authority
HU
Hungary
Prior art keywords
chelators
radiotherapy
compositions
applications
nuclear imaging
Prior art date
Application number
HUE07799253A
Other languages
English (en)
Inventor
David J Yang
Dongfang Yu
David Rollo
Andrew S Thompson
Original Assignee
Univ Texas
Cell Point Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Cell Point Llc filed Critical Univ Texas
Publication of HUE038650T2 publication Critical patent/HUE038650T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HUE07799253A 2006-10-05 2007-07-02 Nukleáris képalkotáshoz és sugárterápiához használt kelátorok (kelátképzõk) hatékony szintézise: összetételek és alkalmazások HUE038650T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82834706P 2006-10-05 2006-10-05
US11/770,395 US10925977B2 (en) 2006-10-05 2007-06-28 Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

Publications (1)

Publication Number Publication Date
HUE038650T2 true HUE038650T2 (hu) 2018-11-28

Family

ID=38667097

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE07799253A HUE038650T2 (hu) 2006-10-05 2007-07-02 Nukleáris képalkotáshoz és sugárterápiához használt kelátorok (kelátképzõk) hatékony szintézise: összetételek és alkalmazások

Country Status (20)

Country Link
US (2) US10925977B2 (hu)
EP (1) EP2079486B1 (hu)
JP (1) JP5541922B2 (hu)
KR (2) KR101606366B1 (hu)
CN (2) CN101678118A (hu)
AU (1) AU2007308022B2 (hu)
BR (1) BRPI0719532B1 (hu)
CA (2) CA2893683C (hu)
DK (1) DK2079486T3 (hu)
ES (1) ES2674910T3 (hu)
HK (1) HK1212634A1 (hu)
HU (1) HUE038650T2 (hu)
IL (2) IL197972A (hu)
NO (1) NO343348B1 (hu)
PL (1) PL2079486T3 (hu)
PT (1) PT2079486T (hu)
RU (1) RU2512491C2 (hu)
SI (1) SI2079486T1 (hu)
TR (1) TR201808820T4 (hu)
WO (1) WO2008045604A2 (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064040A2 (en) * 2006-11-22 2008-05-29 The Board Of Regents Of The University Of Texas System Methods and compositions using chelator-antibody conjugates
WO2009078924A2 (en) * 2007-12-06 2009-06-25 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US8440168B2 (en) * 2008-03-24 2013-05-14 The Board Of Regents Of The University Of Texas System Image-guided therapy of myocardial disease: composition, manufacturing and applications
CN101518656B (zh) * 2009-04-14 2010-12-01 上海师范大学 一种两亲超顺磁性磁共振造影剂
WO2011044377A2 (en) * 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
GB201017088D0 (en) 2010-08-20 2010-11-24 Ge Healthcare Ltd Imaging tuberculosis
US20140161733A1 (en) * 2011-03-30 2014-06-12 Luna Innovations Incorporated Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
BR112014023988B1 (pt) * 2012-03-26 2021-02-02 Board Of Regents, The University Of Texas System método de preparação de um conjugado de tiazolidina-açúcar, composição de conjugado de etilenodicisteína-açúcar e seu uso
CN102743770B (zh) 2012-06-18 2017-07-21 申宝忠 一种靶向性分子成像探针及活体分子成像方法
CN102827208B (zh) * 2012-09-25 2015-01-14 北京师范大学 99mTcO核标记蛋氨酸氨荒酸盐配合物的制备方法和应用
JP6407248B2 (ja) * 2013-03-18 2018-10-17 キアゲン ゲーエムベーハー 細胞外核酸の安定化および単離
JP6163698B2 (ja) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
CN103408477B (zh) * 2013-08-22 2015-06-10 陈鹏飞 一种含砷配位化合物及其制备方法
CN105849568B (zh) * 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
GB201402132D0 (en) * 2014-02-07 2014-03-26 South African Nuclear Energy A method of producing ethylenedicysteine deoxyglucosamine (ECDG) or a salt thereof and its application in a kit
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
WO2016004048A2 (en) 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
GB201421161D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
CN105801362A (zh) * 2014-12-30 2016-07-27 广西梧州制药（集团）股份有限公司 大孔型阳离子交换树脂提升卫矛醇溴化反应收率的用途
CN105801351A (zh) * 2014-12-30 2016-07-27 广西梧州制药（集团）股份有限公司 阳离子交换树脂提升己六醇溴化反应收率的用途
CN105801361B (zh) * 2014-12-30 2019-02-19 广西梧州制药（集团）股份有限公司 一种二取代卫矛醇的合成方法
CN105801356A (zh) * 2014-12-30 2016-07-27 广西梧州制药（集团）股份有限公司 弱酸型阳离子交换树脂提升卫矛醇溴化反应收率的用途
CN105801360B (zh) * 2014-12-30 2018-09-14 广西梧州制药（集团）股份有限公司 一种二溴己六醇的制备方法
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EA201890221A1 (ru) * 2015-07-07 2018-06-29 Файв Илевен Фарма Инк. Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
RU2614695C2 (ru) * 2015-08-12 2017-03-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" Субстрат для производства радиофармпрепарата на основе 99mTc
EP3368546A4 (en) 2015-10-28 2019-06-26 Tarveda Therapeutics, Inc. SSTR TARGETED CONJUGATES, AND ITS PARTICLES AND FORMULATIONS
WO2017090047A1 (en) * 2015-11-27 2017-06-01 Technology Innovation Momentum Fund (Israel) Limited Partnership Glucosamine and derivatives thereof in imaging
WO2018094005A1 (en) * 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
JP6329302B2 (ja) * 2017-05-10 2018-05-23 国立大学法人千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
CN107607504B (zh) * 2017-09-04 2020-10-13 苏州晓松科技开发有限公司 一种用于显现金属客体上生物物证痕迹的生物荧光显现剂及显现方法
CN111362828A (zh) * 2020-03-30 2020-07-03 山西医科大学 一种18f标记的氟丙酰化鸟氨酸及其制备方法和应用
CN112209970B (zh) * 2020-10-21 2021-10-29 北京师范大学 一种锝-99m标记含异腈的谷氨酸-脲衍生物的制备方法和应用
AU2021381323A1 (en) * 2020-11-19 2023-06-22 Cerecin Inc. Radiopharmaceutical ketone and dual tracer imaging in alzheimer's disease, cognitive impairment, and other conditions of altered cerebral metabolism
TW202310881A (zh) * 2021-09-09 2023-03-16 原創生醫股份有限公司 用於超音波造影之金屬複合物及其用途
WO2023077375A1 (en) * 2021-11-04 2023-05-11 Shenzhen Xpectvision Technology Co., Ltd. In vivo xrf agent
CN115583989B (zh) * 2022-12-09 2023-02-28 烟台蓝纳成生物技术有限公司 一种靶向sstr2的化合物及其制备方法和应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141654A (en) * 1977-05-23 1979-02-27 James V. Massey, III Standard for calibrating and/or verifying instrument accuracy
US4279992A (en) * 1978-03-13 1981-07-21 Miles Laboratories, Inc. Specific binding assay employing an enzyme-cleavable substrate as label
US4181654A (en) * 1978-07-24 1980-01-01 The United States Of America As Represented By The United States Department Of Energy 2,3-Dihydroxybenzoic acid amides of tetraazaalkanes and tetaaza cycloalkanes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5648063A (en) * 1981-07-24 1997-07-15 Schering Aktiengesellschaft Sterile composition comprising a chelate complex for magnetic resonance imaging
US4737550A (en) * 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4507466A (en) * 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4568737A (en) * 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5242679A (en) 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
GB8525974D0 (en) * 1985-10-22 1985-11-27 Nyegaard & Co As Chemical substance
US4871779A (en) * 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4694064A (en) * 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4789542A (en) 1986-04-29 1988-12-06 The United States Of America As Represented By The United States Department Of Energy Radioiodinated glucose analogues for use as imaging agents
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4713975A (en) 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
IN165717B (hu) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US4730968A (en) * 1986-09-08 1988-03-15 David Diperstein Self-tapping, self-aligning thread repair insert
US5279811A (en) * 1987-02-18 1994-01-18 The Du Pont Merck Pharmaceutical Company Ester-substituted diaminedithiols and radiolabeled complexes thereof
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US4857599A (en) * 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
US5164294A (en) * 1988-05-17 1992-11-17 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5071965A (en) 1988-07-19 1991-12-10 Mallinckrodt Medical, Inc. Novel tc-99m complexes
US4925650A (en) * 1988-11-16 1990-05-15 Mallinckrodt, Inc. Technetium -99m complex for examining the renal function
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356793A (en) * 1990-03-15 1994-10-18 Nitta Gelatin Inc. Method for testing the sensitivity of anticancer drug
CA2080685A1 (en) 1990-04-17 1991-10-18 Alfons Verbruggen Method and kit for preparing technetium-99m complexes
JPH05508162A (ja) 1990-06-18 1993-11-18 マリンクロッド・メディカル・インコーポレイテッド イソニトリルリガンド含有金属―放射性核種錯化合物
US6096874A (en) * 1990-10-01 2000-08-01 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5385719A (en) * 1991-09-24 1995-01-31 Unger; Evan C. Copolymers and their use as contrast agents in magnetic resonance imaging and in other applications
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
CA2122726A1 (en) * 1991-11-08 1993-05-13 Kattesh V. Katti Multifunctional ligands for potential use in the design of therapeutic or diagnostic radiopharmaceutical imaging agents
US5310536A (en) 1992-02-06 1994-05-10 Mallinckrodt Medical, Inc. Ligands for improving metal chelate formation kinetics
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6033884A (en) * 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
EP1138334A3 (en) * 1992-06-09 2002-04-03 Neorx Corporation Pretargeting methods and compounds
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5620675A (en) * 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5496533A (en) 1992-07-31 1996-03-05 Australian Nuclear Science & Technology Organisation Rhenium complexes
US5605671A (en) * 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
US5684149A (en) * 1993-01-22 1997-11-04 Research Foundation Of State University Of New York Metal complexes for promoting catalytic cleavage of RNA by transesterification
US5834266A (en) * 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5951964A (en) * 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
JPH07126165A (ja) 1993-10-29 1995-05-16 Masao Oguro 腫瘍治療剤
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
WO1995026206A1 (en) * 1994-03-28 1995-10-05 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US6232295B1 (en) * 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
CA2204254C (en) * 1994-11-17 2010-02-16 Stephen Lewis Hart Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US5643883A (en) * 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
HU226646B1 (en) * 1996-03-12 2009-05-28 Pg Txl Company Water soluble pharmaceutical compositions containing taxane derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ATE229968T1 (de) 1996-03-28 2003-01-15 Nihon Mediphysics Co Ltd Diagnostisches mittel zur glykostoffwechselfunktion
US5955053A (en) * 1996-05-06 1999-09-21 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5986074A (en) * 1996-05-06 1999-11-16 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
IT1284046B1 (it) * 1996-06-21 1998-05-08 Bracco Spa Processo per la preparazione di tetraazamacrocicli
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
ES2244006T3 (es) 1996-08-27 2005-12-01 University Of Utah Research Foundation Bioconjugados y administracion de agentes bioactivos.
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6071533A (en) * 1996-11-12 2000-06-06 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
EP0885704B1 (en) * 1996-12-18 2003-08-06 Toray Industries, Inc. Carbon fiber prepreg and method of production thereof
US6187286B1 (en) * 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
US6005083A (en) 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
EP0879606A1 (en) 1997-04-25 1998-11-25 Paul Scherrer Institut Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
NZ500598A (en) * 1997-04-30 2001-09-28 Univ Washington Method of imaging cell death in vivo by administering annexin V labelled with a biocompatible radionuclide (technetium 99 m Tc99m) and measuring the gamma radiation emitted
JP3794517B2 (ja) 1997-05-08 2006-07-05 日本メジフィジックス株式会社 腫瘍診断剤
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
FR2769220B1 (fr) * 1997-10-03 2000-03-10 Oreal Composition oxydante et utilisations pour la teinture, pour la deformation permanente ou pour la decoloration des fibres keratiniques
US6713046B1 (en) * 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
IL136055A0 (en) 1997-11-25 2001-05-20 Genentech Inc Fibroblast growth factor -19
AU2530199A (en) 1998-02-06 1999-08-23 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US6071490A (en) * 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
EP1075287B1 (en) 1998-05-07 2004-02-18 Immunomedics, Inc. Positron emission tomography using gallium-68 chelates
GB9811059D0 (en) 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
IT1302125B1 (it) 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
CA2349333A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
DE19905094C1 (de) 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
AU3699000A (en) 1999-03-10 2000-09-28 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
US20010041189A1 (en) 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
AU3366901A (en) 1999-12-30 2001-07-16 Novartis Ag Novel colloid synthetic vectors for gene therapy
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US6613304B2 (en) 2000-04-20 2003-09-02 University Of British Columbia Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
DE60104421T2 (de) 2000-05-12 2005-09-22 University Hospital Prochelators von radiometall markierten molekülen
US20040072168A1 (en) 2000-05-12 2004-04-15 Wolfgang Knecht Novel deoxynucleoside kinase enzyme variants
DE10024874A1 (de) 2000-05-16 2001-11-29 Siemens Ag Polierflüssigkeit und Verfahren zur Strukturierung von Metallen und Metalloxiden
DK1286704T3 (da) 2000-06-02 2014-09-22 Univ Texas Ethylendicystein (EC)-glucose analoge konjugater
PT1296714E (pt) 2000-06-22 2009-10-15 Coley Pharm Gmbh Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro
US6656450B2 (en) 2000-07-17 2003-12-02 California Institute Of Technology, Inc. Macrocyclic magnetic resonance imaging contrast agents
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
FR2811985A1 (fr) 2000-07-19 2002-01-25 Univ Bretagne Occidentale Procede de synthese de la n1, n3-bis(2-aminoethyl)propane- 1,3-diamine, intermediaires de synthese, produits ainsi obtenus et leur application a la synthese de cyclam
CA2418083A1 (en) 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
CA2425873A1 (en) * 2000-10-19 2002-04-25 The General Hospital Corporation Imaging of enzymatic activity
EA200300572A1 (ru) 2000-11-16 2004-06-24 Фармация Энд Апджон Компани Комбинированная терапия эстроген-зависимых заболеваний
WO2002043775A2 (en) 2000-11-20 2002-06-06 GODFREY, Cullen, M. Paramagnetic metal ion-based macrocyclic contrast agents
JP2004523517A (ja) 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
JP2002241307A (ja) 2001-02-19 2002-08-28 Yasuhiko Tabata 光増感剤を含有する超音波治療用活性酸素発生剤
DE10135355C1 (de) * 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
US20030152512A1 (en) * 2001-11-13 2003-08-14 Milind Rajopadhye Imaging thrombus with glycoprotein llb/llla antagonists
EP1458416A1 (en) 2001-12-13 2004-09-22 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
US7121926B2 (en) * 2001-12-21 2006-10-17 Micron Technology, Inc. Methods for planarization of group VIII metal-containing surfaces using a fixed abrasive article
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
US20050255038A1 (en) 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
EP1562641A4 (en) * 2002-11-07 2008-12-03 Univ Texas CONJUGATES ETHYLENE DICYSTEINE (EC) -MEDICAMENT, COMPOSITIONS AND METHODS FOR IMAGING TISSUE-SPECIFIC DISEASES
EP1583564B1 (en) * 2003-01-13 2009-07-01 Bracco Imaging S.p.A Improved linkers for radiopharmaceutical compounds
US20050024380A1 (en) 2003-07-28 2005-02-03 Lin Lin Method for reducing random access memory of IC in display devices
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
BRPI0511645A (pt) 2004-08-13 2008-01-02 Lg Electronics Inc estabelecimento de conexão de controle de recursos de rádio em sistema de comunicação sem fios
BRPI0606395A2 (pt) * 2005-01-05 2009-06-23 Univ Texas conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações
US20070009428A1 (en) * 2005-07-06 2007-01-11 Syud Faisal A Compounds and methods for enhanced delivery to disease targets
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US7121923B1 (en) 2006-04-20 2006-10-17 Martin P. Gottlieb Dual position sharpening device

Also Published As

Publication number Publication date
US10925977B2 (en) 2021-02-23
RU2512491C2 (ru) 2014-04-10
CA2664826A1 (en) 2008-04-17
IL197972A (en) 2014-03-31
CA2664826C (en) 2015-09-29
SI2079486T1 (en) 2018-08-31
CN101678118A (zh) 2010-03-24
KR101606366B1 (ko) 2016-03-25
IL197972A0 (en) 2009-12-24
US20130039853A1 (en) 2013-02-14
CN104800862A (zh) 2015-07-29
ES2674910T3 (es) 2018-07-04
DK2079486T3 (en) 2018-07-16
PT2079486T (pt) 2018-07-05
AU2007308022B2 (en) 2013-05-09
TR201808820T4 (tr) 2018-07-23
KR20090077942A (ko) 2009-07-16
CA2893683A1 (en) 2008-04-17
JP2010505858A (ja) 2010-02-25
AU2007308022A2 (en) 2009-07-30
PL2079486T3 (pl) 2018-09-28
HK1212634A1 (zh) 2016-06-17
KR101513003B1 (ko) 2015-04-17
EP2079486A2 (en) 2009-07-22
WO2008045604A3 (en) 2009-02-26
BRPI0719532A2 (pt) 2013-02-26
AU2007308022A1 (en) 2008-04-17
JP5541922B2 (ja) 2014-07-09
NO343348B1 (no) 2019-02-04
EP2079486B1 (en) 2018-04-04
BRPI0719532B1 (pt) 2022-03-29
US20080107598A1 (en) 2008-05-08
KR20140140650A (ko) 2014-12-09
NO20091379L (no) 2009-04-21
IL217542A (en) 2014-12-31
RU2009111350A (ru) 2010-11-10
IL217542A0 (en) 2012-02-29
US10814013B2 (en) 2020-10-27
WO2008045604A2 (en) 2008-04-17
CA2893683C (en) 2017-11-28

Similar Documents

Publication Publication Date Title
HK1212634A1 (zh) 用於核成像和放射療法的螫合劑的有效合成:組合物和應用
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
HUS2000041I1 (hu) Triazinonokat és vasat tartalmazó készítmények
IL211835A0 (en) Therapeutic uses of inhibitors of rtp801
IL200576A0 (en) Inhibitors of rtp801 and their uses
IL243294A0 (en) Compounds and compositions for the treatment of cancer
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
ZA200907492B (en) Compositions for targeted imaging and therapy
EP2100870A4 (en) COMPOUND AND COMPOSITION SENSITIVE TO RADIATION
IL194826A0 (en) Compositions and methods for cellular imaging and therapy
EP2129280A4 (en) METHODS OF DIAGNOSIS AND MITIGATION OF GADOLINIUM POISONING
IL201766A0 (en) Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
EP2349311A4 (en) COMPOSITIONS AND METHOD FOR TREATING RADIATION EXPOSURE
GB0708452D0 (en) Treatment of nuclear studge
IL186606A0 (en) Compositions and uses of amooranin compounds
GB0618703D0 (en) Synthesis of leikotriene compounds
ZA200902355B (en) Efficient synthesis of chelators for nuclear imaging and radiotherapy: Compositions and applications
EP1934196A4 (en) CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION
GB0617299D0 (en) Compounds for imaging and therapy
EP2012824A4 (en) USE AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS
GB0612568D0 (en) Isolation of organo-trihydroxyboronate salts and uses thereof
PL116967U1 (pl) Obudowa studzienki kanalizacyjnej